Skip to main content

NIAID SBIR-Technology Transfer — Eligible Inventions (Vaccines and Therapeutics)

By February 25, 2016News
nih-logo

nih-logo

Recent research suggests that the site of vaccine administration significantly influences the tissue specificity and durability of the resulting immune response. Conventional vaccines delivered by intramuscular injection may therefore be unsuitable for the prevention of diseases with tissue tropisms distinct from the site of administration. Notably, for mucosally-transmitted pathogens such as herpes simplex virus (HSV), the current inability to generate a sustain immune response at the primary site of infection, the genital mucosa, has hindered the development effective preventative vaccines.

{iframe}http://www.niaid.nih.gov/researchfunding/sb/Pages/sbir-ttlist-FY2016.aspx{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.